2018
On the Dual Role of Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies
Calinescu A, Turcu G, Nedelcu RI, Brinzea A, Hodorogea A, Antohe M, Diaconu C, Bleotu C, Pirici D, Jilaveanu LB, Ion DA, Badarau IA. On the Dual Role of Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies. Journal Of Immunology Research 2018, 2018: 7169081. PMID: 30406153, PMCID: PMC6204181, DOI: 10.1155/2018/7169081.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigen-related cell adhesion molecule 1Cell adhesion molecule-1Adhesion molecule-1Molecule-1Role of CEACAM1Progression of malignancyPotential new molecular targetsNew molecular targetsPrognostic factorsSpecific cancer therapyPoor prognosisMetastatic spreadSolid cancersCarcinoembryonic antigenTumor progressionCarcinoembryonic antigen familyHuman malignanciesAntigen familyMolecular targetsCancer therapyBiologic functionsConsiderable downregulationMalignancyTumor suppressorEarly phase
2016
CEACAM1: Expression and Role in Melanocyte Transformation
Turcu G, Nedelcu RI, Ion DA, Brînzea A, Cioplea MD, Jilaveanu LB, Zurac SA. CEACAM1: Expression and Role in Melanocyte Transformation. Disease Markers 2016, 2016: 9406319. PMID: 27642217, PMCID: PMC5013198, DOI: 10.1155/2016/9406319.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigen cell adhesion molecule 1Melanoma patientsCell adhesion molecule-1Standard immunohistochemical panelImmune checkpoint inhibitorsSubgroup of patientsAdhesion molecule-1Development of melanomaAggressive therapyCheckpoint inhibitorsAdvanced melanomaPoor prognosisMetastatic melanomaImmunohistochemical panelCell adhesion moleculeMelanoma treatmentMolecule-1New biomarkersPatientsMelanoma progressionAdhesion moleculesMelanoma cellsMelanomaNormal melanocytesTherapy